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A Cluster-Randomized Trial of the ClearGuard HD Antimicrobial
Barrier Cap
Jeffrey L. Hymes, MD,1 Ann Mooney, MSN, RN, CNN,2 Carly Van Zandt, MS,2
Laurie Lynch, PhD,3 Robert Ziebol, BS,3 and Douglas Killion, MBA3
Background: The rate of bloodstream infections (BSIs) is disproportionately high in hemodialysis (HD)
patients with central venous catheters (CVCs) versus those with permanent accesses, contributing to poorer
outcomes, such as increased rates of death and hospitalizations.
Study Design: 12-month, prospective, cluster-randomized, multicenter, open-label trial.
Setting & Participants: 40 Fresenius Medical Care North America dialysis facilities were matched and
paired by positive blood culture rate and number of patients with CVCs and then cluster-randomized with 20 in
each study group. 2,470 patients participated in the study (1,245, intervention group; 1,225, control group),
accruing approximately 350,000 CVC-days.
Intervention: Use of ClearGuard HD Antimicrobial Barrier Caps versus use of standard CVC caps;
assigned at the facility level.
Outcome: Primary end point was positive blood culture rate as an indicator of BSI rate.
Measurements: Positive blood cultures, hospital admissions for BSI, hospitalization-days for BSI,
intravenous antibiotic starts, and CVC-days.
Results: Baseline positive blood culture rates were similar (P 5 0.8) between groups. Use of ClearGuard
HD caps for 12 months was associated with a 56% lower BSI rate versus use of standard CVC caps (0.26 vs
0.59/1,000 CVC-days, respectively; P5 0.01). When considering sustained use (defined as last 6 months of
the study), the intervention versus the control was associated with a 69% lower BSI rate (0.22 vs 0.72/1,000
CVC-days, respectively; P 5 0.01), 43% fewer hospital admissions for BSI (0.28 vs 0.48/1,000 CVC-days,
respectively; P5 0.04), and 51% fewer hospitalization days for BSI (2.42 vs 4.94/1,000 CVC-days,
respectively; P5 0.04). No device-related adverse events were reported.
Limitations: Study was open label; patients occasionally received HD at nonresearch facilities; patients did
not receive the intervention when hospitalized.
Conclusions: The findings show that use of ClearGuard HD Antimicrobial Barrier Caps, when compared
with standard CVC caps, significantly lowers rates of catheter-related BSIs and hospital admissions for BSI in
HD patients using CVCs.
Am J Kidney Dis. 69(2):220-227. ª 2016 The Authors. Published by Elsevier Inc. on behalf of the National
Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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A Novel Device for Reducing BSIsThis study reports results of a novel device, the
ClearGuard HD Antimicrobial Barrier Cap (Pursuit
Vascular, Inc), hereinafter also referred to as the
ClearGuard HD cap, which was recently cleared for
market by the US Food and Drug Administration. As
shown in Fig 1, it is similar to a standard CVC cap,
except the ClearGuard HD cap contains a rod coated
with the antimicrobial agent chlorhexidine acetate.
The rod extends into the CVC hub and has been
shown to reduce the presence of pathogenic organ-
isms in the CVC lock solution proximal to the clamp
by .99.99%.11 Chlorhexidine is a nonantibiotic
antimicrobial agent; thus, the risk for developing
resistant organisms is minimal compared to the use of
antibiotics.12 In addition, it is effective against
antibiotic-resistant organisms.11 The ClearGuard HD
cap is used in the same manner as a standard CVC
cap, without a change to procedural workﬂow.
The following model of the cause of catheter-
related BSI is useful for understanding the Clear-
Guard HD cap mode of action.8,13 Pathogenic
organisms are present in the environment surrounding
the CVC hub. Organisms may be transferred into the
hub during use and at the end of the dialysis pro-
cedure. The planktonic organisms tend to be ﬂushed
into the bloodstream, whereas the sessile organisms
tend to remain in the hub. Between dialysis sessions,
any organisms in the hub are conﬁned between the
CVC cap and clamp within the lock solution, where
they can multiply and form a bioﬁlm. The clamp is
typically repositioned after each dialysis session,
which eventually results in bioﬁlm distal to the clamp.
Organisms within the bioﬁlm can then multiply and
colonize the entire length of the CVC, enter the
bloodstream in increasing quantity, and eventually
overwhelm the immune system, causing a BSI.
The ClearGuard HD cap is intended to prevent this
intraluminal cascade from occurring by killing the
organisms within the lock solution proximal to the
clamp, thus preventing the subsequent steps that lead
to BSI. The ClearGuard HD cap does not eradicate
organisms in a previously colonized CVC and does
not address extraluminal sources of BSI.Figure 1. Attaching ClearGuard HD
Am J Kidney Dis. 2017;69(2):220-227The aim of the study was to investigate whether use
of ClearGuard HD caps in HD patients is associated
with improvements in rates of BSIs, hospital admis-
sions for BSI, hospitalization-days for BSI, and
intravenous (IV) antibiotic starts as compared with
facilities using standard CVC caps.
METHODS
Design
This study was a prospective cluster-randomized comparative-
effectiveness trial intended to evaluate the assigned facilities’ use
of the ClearGuard HD cap. A cluster was deﬁned as a pair of
facilities that were matched for prestudy BSI rate and number of
patients with CVCs using data obtained from March through
August 2014.
Only Fresenius Medical Care North America (FMCNA) facil-
ities not currently participating in another study were eligible to
participate. Forty facilities were matched and paired based on
positive blood culture rate and number of patients with CVCs, then
one of each matched facility pair was randomly assigned using a
computer-generated random number to either begin using Clear-
Guard HD caps (intervention group) or continue using standard
CVC caps (MPC-125 end caps; Molded Products, Inc; control
group). Facility staff members were trained on device use via a
group webinar.
The study was conducted by Frenova Renal Research, with data
collection through FMCNA’s electronic records. The study was
approved by New England Independent Review Board (IRB# 14-
321), which also granted a patient informed consent waiver (TBP
reference TB14-032). The informed consent waiver resulted in
broad inclusion and ease of conducting the study. All HD patients
with a tunneled CVC within each facility were eligible to partic-
ipate unless they had a known allergy to chlorhexidine. All pa-
tients with CVCs in all facilities were treated using the same
FMCNA standard best-practice policies and procedure throughout
the study.14 The only difference in intervention was the type of cap
used.
Standard policies and procedures require that clean gloves,
gown, and full face shield with mask were worn during access
procedures. Prior to accessing the CVC, the exit site was
routinely inspected, the dressing was changed, and the site was
cleaned using 2% chlorhexidine with 70% alcohol swab sticks.
The hub threads were wiped for 15 seconds using a 70% sterile
alcohol pad any time the blood lines were disconnected. Hepa-
rinized saline lock solution was used unless modiﬁed by physi-
cian order. After each dialysis session, a new pair of ClearGuard
HD caps (intervention) or standard CVC caps (control) were
placed on the CVC hubs (typically 3 times per week). When
clinical indications for BSI were present (eg, fever, chills, andCaps to a central venous catheter.
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Hymes et alhypotension), blood cultures were collected from the CVC and/or
peripheral vein.
In order to avoid counting pre-existing BSIs, patients were
censored for the ﬁrst 21 days after entering the study. To avoid
double-counting the same BSI, patients were censored using the
CDC’s National Healthcare Safety Network2recommended 21-
day rule15: a positive blood culture is counted only if it occurred
21 days or more after a previously reported positive blood culture
in the same patient, new positive blood culture events are based on
blood cultures drawn as an outpatient or within 1 calendar day
after a hospital admission, and following a positive blood culture,
hospitalization for BSI, or IV antibiotic start, additional same-type
events are not counted for 21 days following the initial event
(CVC-days are counted during this period). Patients were censored
at CVC removal, death, withdrawal from intervention, or loss to
follow-up.
Evaluation Periods
A 1-month preintervention baseline period occurred in
November 2014. Subsequently, all facilities participated in the 12-
month follow-up from December 1, 2014, through November 30,
2015. Every patient with a CVC who came into a study facility for
dialysis received the facility’s assigned intervention.
Primary and Secondary End Points
The primary end point was comparison of the overall rate of
BSIs (represented by positive blood culture episodes divided by
CVC-days) between patients in the intervention group (Clear-
Guard HD cap facilities) and the control group (standard CVC cap
facilities). Greater than 93% of blood cultures were analyzed by a
single central laboratory.
Secondary end points were rates of hospital admissions and
hospitalization-days for BSI (Item S1) and IV antibiotic starts.
Statistical Analysis
Because randomization was performed with the facility as the
cluster, incidence rate ratios (IRRs) and corresponding 95% con-
ﬁdence intervals (CIs) were calculated using a Poisson regression
model with a log link function and the natural logarithm of patient-
years at risk for offset and adjusted for the facility cluster effect,
where each matched facility pair was considered a cluster. All
statistical analyses were performed using SAS, version 9.3 or
higher (SAS Institute Inc).Table 1. Facility and Patient Charact
Characteristic
Baseline (Nov 2014)
All Intervention Group
No. of facilities 40 20
No. of CVC patients 1,229 618
Age, y 61.16 15.5 61.5 6 15.6
Male sex 624 (51) 321 (52)
Race
White 591 (48) 295 (48)
Black 587 (48) 306 (50)
Other 24 (2) 6 (1)
Missing 27 (2) 11 (2)
Diabetes 722 (59) 363 (59)
Dialysis vintage, y 3.26 4.2 3.06 4.0
Note: Values for categorical variables are given as number (perc
deviation.
Abbreviation: CVC, central venous catheter.
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Cohort Population and Trends
Characteristics of the groups at baseline and
throughout the follow-up period are summarized in
Table 1. Outcomes were analyzed within the sub-
groups of white and nonwhite participants and were
found to be comparable.
All facilities started the study simultaneously on
December 1, 2014; existing HD patients with a
tunneled CVC (hereafter referred to as patients with
CVCs) received the facility’s assigned intervention
at their ﬁrst dialysis session after the study start date,
and new patients with CVCs coming into the facility
were added as appropriate throughout the study.
During the study period, there were 2,912 patients
with CVCs at all 40 participating facilities. Of these,
2,470 patients with CVCs dialyzed for longer than
the 21-day censor period were included in the anal-
ysis. A breakdown of patient disposition is shown in
Fig 2.
In the 1-month baseline period prior to the start of
the study, there were 1,229 patients (618 intervention
and 611 control) who accrued approximately 30,000
CVC-days. This was calculated without imposing 21-
day censoring at the beginning of the baseline period
because the intent was to understand the attributes of
the baseline population prior to the start of the study.
During the 12-month follow-up period, the 2,470
patients in the analysis accrued approximately
350,000 CVC-days. Data are shown by quarters in
Fig 3. The ﬁrst quarter is lower than the other quarters
due to a greater number of patients censored for the
21-day period as they ﬁrst entered the study.
All patients who dialyzed for more than 21 days
and had a standard tunneled CVC were entered
into the study. Additionally, no patients with aneristics at Baseline and Follow-up
Follow-Up (Dec 2014-Nov 2015)
Control Group Intervention Group Control Group
20 20 20
611 1,245 1,225
60.76 15.3 61.5 6 15.1 60.6 6 15.1
303 (50) 654 (53) 666 (54)
296 (48) 609 (49) 631 (52)
281 (46) 566 (46) 495 (40)
18 (3) 17 (1) 40 (3)
16 (3) 53 (4) 59 (5)
359 (59) 705 (57) 698 (57)
3.46 4.3 2.2 6 3.7 2.66 4.0
entage); values for continuous variables, as mean 6 standard
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Patients from 40 Dialysis Facilities 
Treatment Group
Patients from 20 Dialysis Facilities 
1,245 Patients Included in Analysis
568 tunneled CVC patients begin study12/1/2014
877 new tunneled CVC patients join study
• 200 excluded since CVC <21 days
12/2/2014 –
11/30/2015
Transitioned to fistula or
graft (n=509)
Left facility: e.g., death,
lost to follow-up (n=264)
Control Group
Patients from 20 Dialysis Facilities 
1,225 Patients Included in Analysis
579 tunneled CVC patients begin study
888 new tunneled CVC patients join study
• 242 excluded since CVC <21 days
Transitioned to fistula or
graft (n=483)
Left facility: e.g., death,
lost to follow-up (n=283)
Figure 2. Patient count during follow-up period for the intervention and control groups. Abbreviation: CVC, central venous catheter.
A Novel Device for Reducing BSIsappropriate CVC were excluded from study (ie, no
chlorhexidine allergies), and no device-related
adverse events were reported. There were no proto-
col changes during the study.
Primary Outcome: Positive Blood Cultures
During the baseline period, there was no signiﬁcant
difference between the intervention and control
groups (0.56 vs 0.60/1,000 CVC-days; P 5 0.8).
During the follow-up period, there were 153 positive
blood cultures, with 46 in the intervention group and
107 in the control group. There were 346,946 CVC-
days during the follow-up period, with 169,609
CVC-days in the intervention group and 177,337
CVC-days in the control group. The resultant follow-
up positive blood culture rate (adjusted for facility
cluster effect) was 0.26/1,000 CVC-days in the15
36
46
15
37
0
10
20
30
40
50
60
70
Baseline WINTER SP
(NOV 2014) (12/14 - 2/15) (3/15
To
ta
l C
VC
-
)sdnasuoht( syad
Treatment Group (177K CVC-days 12/14
Control Group (170K CVC-days 12/14-1
Figure 3. Central venous catheter (CVC)-days ea
Am J Kidney Dis. 2017;69(2):220-227intervention group versus 0.59/1,000 CVC-days in
the control group (56% less in the intervention group;
P 5 0.01), as shown in Table 2. The positive blood
culture IRR of the intervention compared to the
control was 0.44 (95% CI, 0.23-0.83).
Quarterly results are shown in Fig 4. The rate of
positive blood cultures between groups during the
last 6 months of the study (Fig 5) indicated a sig-
niﬁcant difference: 0.22/1,000 CVC-days in the
intervention group versus 0.72/1,000 CVC-days in
the control group (69% less in the intervention group;
P 5 0.01).
In addition, subgroup analysis of de novo CVCs,
deﬁned as patients who entered the study with a new
CVC, demonstrated a signiﬁcantly lower positive
blood culture rate: 0.16/1,000 CVC-days in the
intervention group versus 0.50/1,000 CVC-days in45 43
50 48
42
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ch period for the intervention and control groups.
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Table 2. Twelve-Month Comparison of Rates for Bloodstream Infections, Cause-Specific Hospitalizations, and IV Antibiotics
Episodes/1,000 CVC-Days Poisson Regression
Intervention Group Control Group IRR (95% CI) P
Primary end point: positive blood culture episodes 0.26 0.59 0.44 (0.23-0.83) 0.01
Secondary end points
No. of hospital admissions for BSI 0.28 0.47 0.60 (0.37-0.97) 0.04
No. of hospitalization-days for BSI 3.24 4.68 0.69 (0.41-1.16) 0.2
No. of IV antibiotic starts 1.68 1.78 0.94 (0.74-1.19) 0.6
Abbreviations: BSI, bloodstream infection; CI, confidence interval; IRR, incidence rate ratio; IV, intravenous.
Hymes et althe control group (68% less in the intervention group;
P 5 0.02; n 5 678 patients).
Secondary Outcomes
Hospital Admissions for BSI
During the baseline period, there was no signiﬁcant
difference between the intervention and control
groups (P 5 0.6) for hospital admissions for BSI.
During the follow-up period, the rate of hospital
admissions for BSI between groups (Table 2)
demonstrated a signiﬁcant improvement: 0.28/1,000
CVC-days in the intervention group versus 0.47/
1,000 CVC-days in the control group (40% less in
intervention group; P 5 0.04).
Comparing rates between groups during the last 6
months of the study (Fig 5) indicated a signiﬁcant
difference: 0.28/1,000 CVC-days in the intervention
group versus 0.48/1,000 CVC-days in the control
group (43% less in intervention group; P 5 0.04).
Hospitalization-Days for BSI
During the baseline period, there was no signiﬁcant
difference between the intervention and control
groups (P 5 0.7) for hospitalization-days for BSI.
During the follow-up period, there were nominally
fewer hospitalization-days in the intervention group
(3.24/1,000 CVC-days) compared to the control0.56
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224group (4.68/1,000 CVC-days), but the difference was
not statistically signiﬁcant (31% less in the interven-
tion group; P 5 0.2; Table 2).
Comparing the rates between groups during the last
6 months of the study (Fig 5) indicated a signiﬁcant
difference: 2.42/1,000 CVC-days in the intervention
group versus 4.94/1,000 CVC-days in the control
group (51% less in intervention group; P 5 0.04).
IV Antibiotic Starts
During the baseline period, there was no signiﬁcant
difference between the intervention and control
groups (P 5 0.4) for new IV antibiotic starts. During
the follow-up period, there were nominally fewer IV
antibiotic starts in the intervention group (1.68/1,000
CVC-days) compared to the control group (1.78/
1,000 CVC-days), but the difference was not statis-
tically signiﬁcant (6% less in intervention group;
P 5 0.6; Table 2).
DISCUSSION
This prospective cluster-randomized comparative-
effectiveness study demonstrated that use of Clear-
Guard HD caps for 12 months was associated with a
56% lower BSI rate versus use of standard CVC caps.
We also observed a 69% lower rate of BSI
(P 5 0.01), 43% fewer hospital admissions for BSI0.18
0.26
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A Novel Device for Reducing BSIs(P 5 0.04) and 51% fewer hospitalization-days for
BSI (P 5 0.04) associated with facilities with sus-
tained use of the ClearGuard HD cap versus facilities
with sustained use of standard CVC caps, where
sustained use was deﬁned as the last 6 months of the
study.
The baseline BSI rate at facilities participating in
this study was better than the national average (0.58/
1,000 vs 0.71/1,000 CVC-days). In addition, the BSI
rate during the 12-month follow-up period at the
control facilities (0.59/1,000 CVC-days; Table 2)
was also better than the national average. Therefore,
results of this study are representative of what would
be expected in better-than-average facilities. The
national average BSI rate is from the 2014 national
aggregate National Healthcare Safety Network
Dialysis Event Surveillance data for “any CVC” of
0.71/1,000 CVC-days.16 This national rate represents
the aggregate pooled mean values from more than
6,000 outpatient HD facilities throughout the United
States. It may be noted that the BSI rate in the control
facilities increased during the follow-up period (Fig
4). Because the study started in the winter, one
possible explanation for the control arm’s increasing
positive blood culture rate over time is the seasonal
trend for the “summer bloom” of bacteremias during
the warmer months.14
This study accepted all patients regardless of CVC
vintage; thus, many CVCs were likely precolonized
with organisms at the beginning of the study.17
Because the mode of action of the ClearGuard HD
cap is to prevent colonization and not eradicate or-
ganisms in a previously colonized CVC, it wasAm J Kidney Dis. 2017;69(2):220-227anticipated that the ClearGuard HD cap might be less
effective with CVCs that had previously used stan-
dard CVC caps. Based on the mode of action, efﬁcacy
was expected to improve over time as old CVCs are
replaced with new CVCs. Therefore, an analysis was
performed in quarterly increments, as shown in Fig 4.
Consistent with the mode of action, there was a lower
positive blood culture rate in the intervention versus
control group during the ﬁrst quarter, which improved
further during the second quarter and was greatest
during the third and fourth quarters. During the last 6
months of the study, the positive blood culture
decrease had reached a sustained level (IRR, 0.31 for
the intervention vs control group; P 5 0.01).
The mode of action also predicts that the device
will be most effective on new CVCs that are only
capped using the ClearGuard HD cap (de novo
CVCs). Results in the de novo CVC subgroup were
comparable to results during the last 6 months of the
study (IRR, 0.32 for the intervention vs control group;
P 5 0.02). These results provide the best indication of
expected sustained performance if ClearGuard HD
caps were fully implemented as standard of care
across all dialysis centers.
Use of ClearGuard HD caps resulted in 6% fewer
IV antibiotic starts in the intervention group versus
the control group, but the difference was not statisti-
cally signiﬁcant. The reason for the smaller than ex-
pected decrease is not fully understood, but it is
known that IV antibiotics are often administered
when a BSI is suspected but might not be present. In
addition, IV antibiotics are administered for other
types of infections, which are often present in this225
Hymes et alpopulation. Finally, in the baseline period prior to the
study, the intervention group had a 25% higher rate of
new IV antibiotic starts versus the control group (3.32
vs 2.66/1,000 CVC-days, respectively; P 5 0.4).
In addition to the important patient-related beneﬁts
resulting from reduced BSIs and hospitalizations, the
resulting economic savings for providers and payers
are substantial. Reducing catheter-related BSIs may
save dialysis providers $2,400 per BSI episode18 and
save Medicare $16,000 per BSI episode,19 primarily
due to reducing missed interventions, medication use,
and hospitalization costs. This equates to a combined
per-member-per-month cost savings of $274 based on
the national average BSI rate (0.71/1,000 CVC-days)
and sustained use of the ClearGuard HD cap (IRR,
0.31). If extended to all HD patients with CVCs in the
United States,20 the estimated combined savings are
conservatively $300 million annually.
This study has many strengths. It was prospective
and randomized and used best-practice methods for
infection prevention in the control arm. All facilities
followed standard clinical policies and procedures
throughout the study, except for using the ClearGuard
HD cap at intervention group facilities; therefore,
results are representative of use in current clinical
practice. Also, it was of 12 months’ duration, so
seasonal variations and sustainability were assessed.
In addition, it was larger than any reported antimi-
crobial lock meta-analysis study to date.4,5,21,22
The study also has limitations. It was open label,
and intervention patients occasionally received dial-
ysis at nonparticipating facilities, which likely
diminished the effectiveness of the intervention. Not
all positive blood culture measurements were
captured, such as during hospitalization; therefore,
BSI rates are under-reported. In addition, diagnosis-
speciﬁc hospitalizations are not always accurately
coded and were likely underestimated due to barriers
preventing complete access to hospital discharge re-
cords23,24; however, there was no indication that po-
tential biases were unbalanced between groups. In
consideration of these issues, the study is likely
generalizable to other dialysis facilities with similar
patient populations and intervention practices.
In summary, our ﬁndings show that the ClearGuard
HD cap, when compared to a standard CVC cap,
signiﬁcantly lowers rates of catheter-related BSI and
hospital admissions for BSI, representing an impor-
tant breakthrough for HD patient care in the United
States.
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